Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2023-01-24 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new digital therapeutics solution called LYFE by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations, indicating it is a regulatory announcement. The content focuses on product launch and company information rather than financial results, management changes, or shareholder voting. The document length is 5619 characters, which is relatively short and typical for a press release. There is no financial data, no mention of annual or quarterly reports, no audit information, no legal proceedings, no capital changes, or other specific report types. Therefore, this document fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure under SEBI regulations.
2023-01-24 English
Lupin Launches LYFE, its Digital Therapeutic Solution for Holistic Heart Care.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new digital therapeutics solution called LYFE by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The content focuses on product launch information and company background, without any financial data, earnings, management changes, or regulatory filings. It is not a financial report, earnings release, management discussion, or regulatory filing. It is a corporate announcement related to business activities but does not fit into categories like M&A, capital updates, or governance. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2023-01-24 English
ESOP/ESOS/ESPS
Regulatory Filings Classification · 95% confidence The document text is extremely short (569 characters) and contains only a digital signature block with no substantive content related to financial performance, management changes, or any specific report. There is no mention of any report, meeting, or financial data. Given the lack of content and the presence of a digital signature, this document is likely an officer certification or attestation. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2023-01-20 English
Disclosure pursuant to allotment of 114899 shares under ESOP.
Regulatory Filings Classification · 100% confidence The document text is extremely short (516 characters) and consists solely of a digital signature block with no substantive content related to financial reports, announcements, or filings. There is no mention of any report type, financial data, regulatory body, or corporate event. Given the lack of content and the nature of the text, it does not fit any specific filing category and should be classified as a Regulatory Filing (RNS), which serves as a fallback category for miscellaneous filings that do not fit elsewhere.
2023-01-20 English
Lupin Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new pharmaceutical product by Lupin Limited. It is addressed to stock exchanges and references compliance with SEBI regulations for disclosure. The content focuses on product launch information and company background, without any financial statements, earnings data, or regulatory filings. It is not an annual report, earnings release, management report, or any other detailed financial or governance document. The document is a corporate announcement intended for public dissemination about a new product launch, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement and disclosure under listing obligations.
2023-01-18 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new combination drug by Lupin Limited. It is addressed to stock exchanges and references compliance with SEBI regulations for disclosure. The content focuses on product launch information, market context, and company background. There are no financial statements, earnings data, management discussion, or regulatory filings beyond the disclosure notice. The document is approximately 5,520 characters, which is relatively short and primarily serves as a public announcement rather than a detailed financial or regulatory report. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2023-01-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.